ArticleInternational journal of molecular sciences2025
Silver Nanoparticle-Induced Nephrotoxicity in Zebrafish (
Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Biologically Mediated Nanoparticle Synthesis as a Potential Green Strategy: Principles, Methods, and Pharmaceutical Applications.Pharmaceutics · 2026Review
- Silver Nanoparticles (AgNPs) as a Double-Edged Sword: Synthesis, Factors Affecting, Mechanisms of Toxicity and Anticancer Potentials-An Updated Review till March 2025.Biological trace element research · 2026Review
- Effects of Nano-Silver Exposure on Oxidative Stress, Transcriptome, and Intestinal Microbiota ofBiology · 2025Article
- Microbial-Based Green Synthesis of Silver Nanoparticles: A Comparative Review of Bacteria- and Fungi-Mediated Approaches.International journal of molecular sciences · 2025Review
- Acute Dermatotoxicity of Green-Synthesized Silver Nanoparticles (AgNPs) in Zebrafish Epidermis.Toxics · 2025Article
- Functional Feed for Tilapia: Exploring the Benefits ofBiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The escalating challenge of antibacterial resistance has driven the widespread use of silver nanoparticles (AgNPs) due to their potent antimicrobial properties. AgNPs can be synthesised through diverse methods, spanning conventional chemical and physical routes to the increasingly favoured biosynthesis approach. While offering environmental advantages, the ecological impact of biogenically synthesized AgNPs, especially on aquatic ecosystems, requires thorough evaluation. The renal system, critical for maintaining physiological homeostasis via nephron-mediated waste removal, fluid regulation, and electrolyte balance, is highly vulnerable to toxicant-induced damage, which can negatively affect organismal fitness. This study aimed to assess the nephrotoxic effects of AgNPs, synthesized using entirely "green" methods, on zebrafish after 96-h exposures to three distinct concentrations alongside a control group. Acridine orange fluorescence microscopy revealed dose-dependent histopathological alterations in renal tissues. Specifically, at 0.031 μg/L and 0.250 μg/L, significant changes were observed, including glomerular shrinkage, proliferation of hematopoietic tissue, dissociation and dilation of renal tubules, and melanomacrophage aggregation. At 5.000 μg/L, prolonged exposure beyond 48 h indicated a potential for renal tissue cell renewal, suggesting a possible compensatory response. These results demonstrate the sensitivity of zebrafish kidneys to AgNPs and emphasize the imperative for comprehensive in vivo toxicity testing, irrespective of synthesis method, to accurately evaluate the potential for adverse ecological impacts and ensure the preservation of aquatic ecosystem integrity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.